Document Detail

Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
MedLine Citation:
PMID:  12777996     Owner:  NLM     Status:  MEDLINE    
Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to the analysis of p53. We have studied a series of 100 primary colorectal adenocarcinomas by immunohistochemistry with the monoclonal antibody PAb1801, and single-stranded conformation polymorphism (PCR-SSCP, exons 4-8) followed by direct sequencing of shifted bands. p53 Nuclear staining was undetectable (score 0) in 29 of 100 cases. However, gene mutations were detected in 15 of these cases, with all of these mutations leading to abnormal proteins. p53 Nuclear staining was detectable and scored as less than 10% tumor cells positive in 15 of 100 cases but was still considered to be displaying a p53-negative phenotype because the cut-off value for positivity was 10% positive tumor cells. Nevertheless, TP53 gene mutations were detected in 2 of these cases. p53 Nuclear immunoreactivities were detectable and scored as more than 10% tumor cells positive in 56 cases, considered the p53-positive phenotype. TP53 gene mutations were identified in 51 of these 56 cases. These results reveal that immunohistochemical assessment does not predict TP53 mutation status in colorectal adenocarcinoma, mainly in cases displaying absence of nuclear staining. It is thus concluded that molecular profiling should be conducted in parallel with immunophenotyping when analyzing colorectal tumors for p53 status.
Anna Colomer; Nadina Erill; Montse Verdú; Ruth Roman; August Vidal; Carlos Cordon-Cardo; Xavier Puig
Related Documents :
9192806 - Frequent mutation of the e2f-4 cell cycle gene in primary human gastrointestinal tumors.
9496836 - Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associate...
11212236 - Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurren...
9230196 - Normal polymorphism in the incomplete trinucleotide repeat of the arginine-rich protein...
24573556 - Ubiquitin-like with phd and ring finger domains 2 is a predictor of survival and a pot...
17167646 - Skull base neurocytoma: case report and review of the literature of extraventricular ne...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry     Volume:  11     ISSN:  1541-2016     ISO Abbreviation:  Appl. Immunohistochem. Mol. Morphol.     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-02     Completed Date:  2004-04-23     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  100888796     Medline TA:  Appl Immunohistochem Mol Morphol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  130-7     Citation Subset:  IM    
BIOPAT, Grup Assistència, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / genetics
Aged, 80 and over
Colorectal Neoplasms / genetics*
DNA Mutational Analysis
Data Interpretation, Statistical
Gene Frequency
Genes, p53 / genetics*
Middle Aged
Tumor Suppressor Protein p53 / analysis*,  genetics
Reg. No./Substance:
0/Tumor Suppressor Protein p53

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Zonula occludens-1 and Her-2/neu expression in invasive breast carcinoma.
Next Document:  p27 and cyclin E/D2 associations in testicular germ cell tumors: implications for tumorigenesis.